Sepracor - Journal Publications: LUNESTA(R) (eszopiclone)

1. Botteman MF, Ozminkowski RJ, Wang S, Pashos CL, Schaefer K, Foley DJ. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults. CNS Drugs 2007;21(4):319-334.

2. Krystal A, Fava M, Rubens R, Wessel T, Caron J, Wilson P, Roth T, McCall WV. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. Journal of Clinical Sleep Medicine 2007; 3(1):48-55.

3. Krystal A. Treating the health, quality of life, and functional impairments in insomnia. Journal of Clinical Sleep Medicine 2007;3(1):63-72.

4. Meltzer LJ, Mindell JA, Owens JA, Byars KC. Use of sleep medications in hospitalized pediatric patients. Pediatrics 2007;119:1047-1055.

5. Ozminkowski RJ, Wang S, Walsh JK. The direct and indirect costs of untreated insomnia in adults in the United States. SLEEP 2007;30(3):263-273.

6. Rosenberg R, Roach JM, Scharf M, Amato DA. A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome. Sleep Med (2007)8:464-470.

7. Roth T, Roehrs T, Pies, R. Insomnia: Pathophysiology and implications for treatment. Sleep Medicine 2007;11:71-79.

8. Walsh JK, Krystal AD, Amato DA, Rubens R, Caron J, Wessel TC, Schaefer K, Roach J, Wallenstein G, Roth T. Nightly treatment of primary insomnia with eszopiclone for six months: Effect on sleep, quality of life, and work limitations. Sleep 2007;30(8):959-968.

2006 LUNESTA (eszopiclone) Publications

1. Fava M, McCall WV, Krystal A et al. Eszopiclone Co-Administered With Fluoxetine in Patients With Insomnia Coexisting With Major Depressive Disorder. Biol Psychiatry 2006, 59(11):1052-1060.

2. Fava M, McCall V, Krystal A et al. Eszopiclone co-administered with fluoxetine for insomnia co-existing with Major Depressive Disorder (MDD): analysis by severity of depression. Abstracts of the 46th Annual NCDEU Meeting. 2006.

3. McCall WV, Erman M, Krystal AD, Rosenberg R, Scharf M, Zammit GK, Wessel T. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion 2006, 22(9):1633-1642.

2005 LUNESTA (eszopiclone) Publications

1. Rosenberg R, Caron J, Roth T, Amato D. An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Sleep Medicine 2005:6:15- 22.

2. Scharf M, Erman M, Rosenberg R, Seiden D, McCall WV, Amato D, Wessel TC. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. SLEEP 2005; 28(6):720-727.

3. Tarantino P, Appleton N, Lansdell K. Effect of Trazodone on hERG channel current and QT-interval. European Journal of Pharmacology 2005; 510:75-85.

2004 LUNESTA (eszopiclone) Publications

1. Ancoli-Israel S, Lieberman JA. Introduction. Postgraduate Medicine 2004, Suppl:4-6.

2. Ancoli-Israel S, Soares CN, Gaeta R, Benca RM. Insomnia in special populations. Postgraduate Medicine 2004; Suppl:33-47.

3. Benca RM. Behavioral and pharmacologic management options for insomnia. Postgraduate Medicine 2004; Suppl:23-32.

4. Benca RM, Ancoli-Israel S, Moldofsky H. Special considerations in insomnia diagnosis and management: depressed, elderly, an chronic pain populations. J Clin Psychiatry 2004; 65(Suppl8):26-35.

5. Buysse DJ, Amato D, Wilson P, Wessel T. Trajectory analysis of treatment response during a six-month study of nightly eszopiclone in patients with chronic insomnia. SLEEP 2004, 27 Suppl:A262-A263.

6. Caron J, Wessel T, Maier G. Evaluation of a pharmacokinetic interaction between eszopiclone and digoxin. SLEEP 2004, 27 Suppl:A54.

7. Doghramji PP. Practical diagnostic strategies and tools for insomnia. Postgraduate Medicine 2004; Suppl:14-22.

8. Edinger JD. Classifying insomnia in a clinically useful way. J Clin Psychiatry 2004:65(Suppl8):36-43.

9. Erman M, Rosenberg R, Caron J. Polysomnographic and patient-reported evaluation of the efficacy and safety of eszopiclone in elderly subjects with chronic insomnia. SLEEP 2004, 27 Suppl:A257-A258.

10. Erman MK, Wessel T. Consistency of patient reported measures of efficacy and next-day functioning of eszopiclone in adults with chronic insomnia. 157th Annual Meeting of the American Psychiatric Association. New York, NY 2004. pp296

11. Israel AG, Lieberman JA. Tackling insomnia. Postgraduate Medicine 2004; Suppl:7-13.

12. Krystal A, Roach J, Caron J. Efficacy of eszopiclone in the treatment of sleep maintenance insomnia: a subset analysis by baseline wake after sleep onset (WASO). SLEEP 2004, 27 Suppl:A257.

13. Krystal A, Roach J. Efficacy of eszopiclone in the treatment of sleep-maintenance insomnia. 157th Annual Meeting of the American Psychiatric Association 2004. New York, NY pp. 318

14. Krystal A. The changing perspective on chronic insomnia management. J Clin Psychiatry 2004; 65(Suppl8):20-25.

15. Krystal A, Roth T. Definitions, measurements, and management in insomnia. J Clin Psychiatry 2004: 65(Suppl8):5 - 7.

16. Maier G, Rubens, R, Amato, D. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of eszopiclone: a comparison of healthy non-elderly and elderly adults. SLEEP 2004, 27 Suppl:A56.

17. Maier G, Roach J, Rubens R. Evaluation of pharmacokinetic and pharmacodynamic interactions between eszopiclone and warfarin. SLEEP 2004, 27 Suppl:A56.

18. McCall V, Zammit G, Scharf M, Roach J, Amato D. A pooled analysis of eszopiclone in the treatment of insomnia in the elderly. SLEEP 2004, 27 Suppl:A261.

19. McCall WV, Rosenberg R, Caron J. Polysomnographic evaluation of the efficacy and safety of eszopiclone in elderly patients with chronic insomnia. 157th Annual Meeting of the American Psychiatric Association 2004. New York, NY pp.318-319.

20. McCall WV. Sleep in the elderly: burden, diagnosis and treatment. Prim Care Companion J Clin Psychiatry 2004, 6(1):9-20.

21. Rosenberg R, Rubens R. Four studies of eszopiclone indicate consistent efficacy in non-elderly and elderly patients with chronic insomnia. 157th Annual Meeting of the American Psychiatric Society 2004. New York, NY. pp. 319.

22. Roth T, Krystal A, Walsh J, Roehrs T, Wessel T, Caron J. Twelve months of nightly eszopiclone treatment in patients with chronic insomnia: assessment of long-term efficacy and safety. SLEEP 2004, 27 Suppl:A260.

23. Roth T, Krystal A, Wessel T, Caron J. An assessment of the long-term efficacy and safety of eszopiclone over twelve months of nightly treatment in patients with chronic insomnia. 157th Annual Meeting of the American Psychiatric Association 2004. New York, NY. pp. 315.

24. Roth T. Measuring treatment efficacy in insomnia. J Clin Psychiatry 2004; 65(Suppl8): 8 - 12.

25. Scharf M, McCall WV, Erman M, Rubens R. Patient-reported efficacy of eszopiclone (ESZ) in elderly patients with chronic insomnia. Journal of the American Geriatrics Society 2004, 52(4) Suppl:S14.

26. Scharf M, Rosenberg R, Zammit G, Roach J. Eszopiclone efficacy and daytime functioning in non-elderly and elderly patients with chronic insomnia. SLEEP 2004, 27 Suppl: A258.

27. Walsh JK. Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry 2004; 65(Suppl8):13 - 19.

28. Zammit G, Caron J, Roth T. A six-week efficacy and safety study of eszopiclone in adult patients with chronic insomnia. 157th Annual Meeting of the American Psychiatric Association 2004. New York, NY pp. 319.

29. Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Current Medical Research and Opinion 2004, 20(12):1979-1991.

2003 LUNESTA (eszopiclone) Publications

1. Krystal AD; Walsh JK; Laska E, Caron J, Amato DA, Wessel TC, Roth T. Sustained efficacy of Eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. SLEEP 2003;26(7):793-9.